New technology platforms in the development of vaccines for the future (Q35023493)

5 August 2017

1 reference

title

New technology platforms in the development of vaccines for the future (English)

1 reference

5 August 2017

Glück R

1

1 reference

PubMed ID

12477412

5 August 2017

Metcalfe IC

series ordinal

2

1 reference

PubMed ID

12477412

5 August 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

5 August 2017

1 reference

5 August 2017

20 Suppl 5

1 reference

5 August 2017

B10-6

1 reference

The development and use of vaccine adjuvants

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Improvement of inactivated influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Mechanisms of adjuvancy: I--Metal oxides as adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Immunogenicity of new virosome influenza vaccine in elderly people

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Infectious entry pathway of influenza virus in a canine kidney cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Structure-function relationships among highly diverse T cells that recognize a determinant from influenza virus hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Immunostimulating complexes (ISCOMs) for nasal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Mucosal immunity and vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Altered eosinophil levels as a result of viral infection in asthma exacerbation in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Perspectives: towards a peptide-based vaccine against hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Enhanced cytotoxicity of doxorubicin encapsulated in liposomes with reconstituted Sendai F-proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Exploiting conformationally constrained peptidomimetics and an efficient human-compatible delivery system in synthetic vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Targeting influenza virosomes to ovarian carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

1 reference

7 January 2021

c-DNA vaccination against parasitic infections: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

DNA vaccine against malaria: a long way to go.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Gene therapy: optimising DNA delivery to the nucleus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Oral somatic transgene vaccination using attenuated S. typhimurium.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Attenuated deltaguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Delivery of DNA vaccines by attenuated intracellular bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Recombinant measles viruses efficiently entering cells through targeted receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Effect of high-affinity anti-Pseudomonas aeruginosa lipopolysaccharide antibodies induced by immunization on the rate of Pseudomonas aeruginosa infection in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2802%2900513-3

7 January 2021

10.1016/S0264-410X(02)00513-3

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12477412